Healthcap is an active, long-term manager which invests in pharmaceutical, biotechnology and medical technology companies globally. As a multi-stage fund, the firm provides and participates in financing through all stages of company evolution. Their funds have no geographic restrictions.Healthcap's main investment style is to be lead investor and the firm acts predominantly as an influential minority investor, seeking to invest in the commercialization of innovations in medical science where they believe that the structural changes taking place in the pharmaceutical industry create significant opportunities for knowledgeable investors to achieve high financial returns.The firm partners with investee companies and founders, seeking board representation to assist with strategy formulation in the areas of science, business development and finance. They encourage substantial ownership by entrepreneurs and scientific founders and insist on implementing employee equity ownership programs to attract and reward key personnel.Healthcap's in-house science team evaluates the scientific merits of investment proposals and their in-house transaction team structures the transactions. The firm invests independently or in partnership with other investor groups.
Orexo AB engages in the development of pharmaceuticals based on innovative drug delivery technologies. Its focuses on the treatment of opioid dependence. It distributes its products under the following brands: Zubsolv, Abstral, and Edluar. The company was founded by Thomas Lundqvist, Anders Pettersson, and Lars Christer Nyström on November 18, 1994 and is headquartered in Uppsala, Sweden.
Creative Antibiotics AB is engaged in the development of antibacterial agents. It was established to commercialise research, principally at Umeå University, Karolinska Institute and Stockholm University. The company was founded in 2000 and is headquartered in Umeå, Sweden.